N/A N=80 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection
Lymph Node Dissection · Lymphoedema · Lymphocoele
Primary: Postoperative Draining Time — 31; 32 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
N/A N=20 Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection
Cancer of the Urinary Tract
Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants
N/A N=934 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
Breast Cancer
Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004
Phase 3 N=28 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate
Phase 2 N=90 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
Stage I Papillary Thyroid Cancer · Stage II Papillary Thyroid Cancer · Stage III Papillary Thyroid Cancer
Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…
N/A N=228 Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast
Intraductal Carcinoma and Lobular Carcinoma in Situ
Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants
Phase 4 N=74 Post-Operative Drainage Following Lymph Node Dissection
Malignant Melanoma · Carcinoma, Squamous Cell
Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704
Phase 4 N=41 LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients
Head and Neck Neoplasms
Primary: Opreation Duration — 97.1; 116.3 minutes — p=0.022
Phase 2 N=11 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder
Bladder Cancer
Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Phase 3 N=5,611 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer
Breast Cancer
Primary: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit — 276; 200 Participants
N/A N=120 Prevention of Lymphoceles After Robotic PLND
Lymphoceles · Prostate Cancer
Primary: Incidence of Lymphoceles — 10; 12; 104; 102 participants — p=0.412
Phase 3 N=186 Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 0.9767 Proportion of Lymph Nodes
N/A N=32 Fibrin Glue in Inguinal Lymphadenectomy
Seroma
Primary: Number of Participants With Seroma Formation — 2; 8 participants — p=0.022
N/A N=9 Intraoperative Evaluation of Axillary Lymphatics
Lymphedema · Surgery · Breast Cancer
Primary: Number of Cases Where Lymphatics Were Visualized by Blue Dye Versus by ICG Using the OnLume Imaging System — 5; 9 Participants
Phase 2 N=30 Lymphatic Mapping for Sentinel Node Identification and Analysis
Colorectal Cancer
Primary: Subjects in Which the SLN(s) Are Identified — 27 Participants
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
Phase 2 N=756 Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Breast Cancer
Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…
N/A N=89 Infrared Lymphangiography as a Method of Sentinel Node Identification
Melanoma · Sentinel Node
Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient
Phase 2 N=62 Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)
Breast Cancer
Primary: The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel…
N/A N=568 Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Lymphedema
Primary: Number of Participants Who Were Lymphedema-free 18 Months After Randomization — 114; 135 Participants
Phase 4 N=40 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer
Breast Cancer
Primary: Injection Site Clearance for Lymphoseek and 99mTc-Sulfur Colloid (SC). — 1.78; 0.045 minutes
N/A N=112 Fibrin Melanoma Axillary Node Study in Patients With Melanoma
Melanoma
Primary: Drain Duration — 23; 21 days
Phase 1 N=22 Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients
Carcinoma
Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…
Phase 2 N=3 Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Head and Neck Cancer
Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
N/A N=57 Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery
Rectum Cancer
Primary: The Blood Pressure of the Arterial Arcade — 42.31; 48.50 mmHg
N/A N=592 S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Bladder Cancer
Primary: 5-year Disease-free Survival (DFS) — 60; 56 percentage of participants — p=0.45